Related Experiment Video
Updated: May 9, 2025

05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
1.9K
Deep neural network base competing risk in predicting heart failure patient's survival
Solmaz Norouzi1, Ebrahim Hajizadeh1, Mohammad Asghari Jafarabadi2,3
1Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Journal of Diabetes and Metabolic Disorders
|May 2, 2025
Summary
Deep Neural Network Competing Risks (DNNCR) models better predict survival outcomes in heart failure (HF) patients than Random Survival Forest (RSF) models. This AI approach aids in identifying high-risk individuals for tailored treatment strategies.
Area of Science:
- Cardiology
- Biostatistics
- Artificial Intelligence
Background:
- Heart failure (HF) presents complex prognostication challenges due to competing risks like HF-specific mortality and other causes of death.
- Accurate prediction of time-to-event outcomes is crucial for effective patient management in HF.
Purpose of the Study:
- To compare the predictive performance of a Deep Neural Network Competing Risks (DNNCR) model against a Random Survival Forest (RSF) model for time-to-event outcomes in HF patients.
- To evaluate the models' ability to handle competing risks in survival analysis for heart failure.
Main Methods:
- Retrospective analysis of 435 heart failure patients with a five-year follow-up.
- Application of Deep Neural Network Competing Risks (DNNCR) and Random Survival Forest (RSF) models to analyze survival data with competing risks.
- Model performance assessed using the C-index and Integrated Brier Score (IBS).
Main Results:
- The DNNCR model demonstrated superior predictive performance compared to RSF, indicated by higher C-index values for both HF-specific death and other causes of death.
- DNNCR achieved a C-index of 0.65 for HF and 0.63 for other causes, outperforming RSF's C-indices of 0.65 and 0.61, respectively.
- Calibration analysis using IBS showed the DNNCR model's superior performance with IBS values of 0.16 for HF and 0.18 for other causes.
Conclusions:
- The DNNCR model significantly outperforms the RSF model in predicting survival outcomes for heart failure patients, especially when dealing with competing risks.
- Enhanced predictive accuracy facilitates better identification of high-risk patients, enabling personalized treatment strategies.
- Future research should focus on diverse datasets to improve DNNCR performance and clinical integration.
Related Concept Videos
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Heart Failure Drugs: β-Blockers
259
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
259

